Literature DB >> 18022548

Current immunotherapeutic strategies in breast cancer.

William E Carson1, Margaret I Liang.   

Abstract

Despite significant advances in the administration of combination cytotoxic chemotherapy, the overall 5-year survival rate is about 75% for a woman who has node-positive breast cancer, and metastatic disease is considered incurable. Recent advances in our understanding of the immune system have led to the hope that manipulation of this organ system could be used as a cancer treatment. Strategies that have been used in the immune therapy of breast cancer include the administration of exogenous cytokines, vaccines, and humanized monoclonal antibodies (mAb). Each of these approaches is discussed in turn in this article.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18022548     DOI: 10.1016/j.soc.2007.07.008

Source DB:  PubMed          Journal:  Surg Oncol Clin N Am        ISSN: 1055-3207            Impact factor:   3.495


  4 in total

1.  Biobehavioral, immune, and health benefits following recurrence for psychological intervention participants.

Authors:  Barbara L Andersen; Lisa M Thornton; Charles L Shapiro; William B Farrar; Bethany L Mundy; Hae-Chung Yang; William E Carson
Journal:  Clin Cancer Res       Date:  2010-06-08       Impact factor: 12.531

2.  Targeting Tissue Factor for Immunotherapy of Triple-Negative Breast Cancer Using a Second-Generation ICON.

Authors:  Zhiwei Hu; Rulong Shen; Amanda Campbell; Elizabeth McMichael; Lianbo Yu; Bhuvaneswari Ramaswamy; Cheryl A London; Tian Xu; William E Carson
Journal:  Cancer Immunol Res       Date:  2018-04-05       Impact factor: 11.151

3.  Myeloid-derived suppressor cells are increased and correlated with type 2 immune responses, malnutrition, inflammation, and poor prognosis in patients with breast cancer.

Authors:  Kenji Gonda; Masahiko Shibata; Tohru Ohtake; Yoshiko Matsumoto; Kazunoshin Tachibana; Noriko Abe; Hitoshi Ohto; Kenichi Sakurai; Seiichi Takenoshita
Journal:  Oncol Lett       Date:  2017-06-02       Impact factor: 2.967

4.  IL-12 enhances the antitumor actions of trastuzumab via NK cell IFN-γ production.

Authors:  Alena Cristina Jaime-Ramirez; Bethany L Mundy-Bosse; SriVidya Kondadasula; Natalie B Jones; Julie M Roda; Aruna Mani; Robin Parihar; Volodymyr Karpa; Tracey L Papenfuss; Krista M LaPerle; Elizabeth Biller; Amy Lehman; Abhik Ray Chaudhury; David Jarjoura; Richard W Burry; William E Carson
Journal:  J Immunol       Date:  2011-02-14       Impact factor: 5.422

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.